The CV and kidney protective effects of the GLP-1 RAs and the SGLT2 inhibitors in particular has significantly changed the management of patients with T2D, who are at increased risk for adverse CV and kidney outcomes (13–16). This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.